Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Correlation Between Programmed Death-Ligand1 Expression and Clinical Outcomes After Neoadjuvant Systemic Therapy in Her-2 Positive and Triple Negative Breast Cancer

NCT05169853 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT05169853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Correlation Between Programmed Death-Ligand1 Expression and Clinical Outcomes After Neoadjuvant Systemic Therapy in Her-2 Positive and Triple Negative Breast Cancer
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2022
Completion date
October 30, 2024
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, triple negative breast cancer